$410 million Anchen becomes second generics firm to come in under Par
This article was originally published in Scrip
Executive Summary
Par Pharmaceutical will buy the privately held US generic drug maker Anchen Pharmaceuticals for $410 million in cash, thereby significantly expanding its pipeline opportunities and formulation capabilities. Anchen specialises in extended-release products and has aggressively challenged patents of brand companies, targeting first-to-file ANDA opportunities.